CA-GLOBALLOGIC
13.10.2021 14:03:13 CEST | Business Wire | Press release
GlobalLogic Inc. , a Hitachi Group Company and leader in Digital Engineering, today announced that it has been selected by Inspira Technologies to develop an algorithm-enhanced digital platform powering the ART device — an Early Extracorporeal Respiratory Support system targeting respiratory failure patients such as those diagnosed with COVID-19. The project underscores GlobalLogic’s deep expertise in Class II and Class III software creation for medical devices that must meet strict regulatory requirements.
Inspira Technologies created the ART, a novel low-flow early extracorporeal approach to address the significant patient population whose condition continues to deteriorate following noninvasive ventilation. As of today, the only treatment available for them after noninvasive ventilation is the highly invasive mechanical ventilation. The ART device utilizes a hemo-protective flow approach designed to rebalance oxygen saturation levels while patients are awake and breathing spontaneously, potentially minimizing the need for mechanical ventilation. The ART is designed to enrich ~200cc of blood at any given point, elevating the oxygen saturation levels in one minute.
GlobalLogic will support Inspira in the development of the ART control platform’s algorithms responsible for monitoring and managing the early rebalancing of the patient’s oxygen saturation levels. These algorithms will also activate and control proprietary technologies and data collected from advanced sensors that measure oxygen saturation, blood temperature, hemoglobin, and hematocrit levels as well as blood pressure and flow. Inspira Technologies notes that the ART could potentially minimize the need for mechanical ventilators for hypoxemic patients, such as COVID patients. Additionally, GlobalLogic will be leading the verification testing of these systems.
“Software plays an increasingly more crucial role in driving the overall efficacy of medical devices today. It also enhances the patient engagement with and medical staff’s use of such technologies,” said Shashank Samant, President & CEO, GlobalLogic. “For nearly twenty years, we’ve worked with world-renowned medical device manufacturers as well as start-ups in today’s MedTech innovation hotspots. We’re honored to have the opportunity to play such a pivotal role in bringing to market another disruptive technology, the ART. Particularly at such a critical time when there is a dire need for advanced treatment options.”
GlobalLogic possesses deep competencies centered around key medical device capabilities: device performance; data collection and analysis; and intuitive medical personnel and patient experiences. Specific to the ART, GlobalLogic’s engineering contributions will help Inspira Technologies produce a digitally enhanced artificial lung while empowering medical staff with vital patient stats needed to easily monitor progress and effectiveness.
“It was imperative that we find a partner with both specialized MedTech capabilities and the scale needed to meet our design objectives as we are committed to bring to market a much-needed technology — filling a critical gap in today’s medical treatment options for respiratory failure patients who continue to deteriorate after treatment with noninvasive ventilation devices. Our decision to partner with GlobalLogic was driven by its proven ability in the medical device landscape and the capacity to meet aggressive time-to-market requirements with reliable solutions,” explained Dagi Ben-Noon, CEO, Inspira Technologies.
ART is currently in development with anticipated regulatory submission of its ART ECLS at the end of 2022.
About GlobalLogic
GlobalLogic (www.globallogic.com ) is a leader in digital product engineering. We help brands across the globe design and build innovative products, platforms, and digital experiences for the modern world. By integrating experience design, complex engineering, and data expertise — we help our clients imagine what’s possible and accelerate their transition into tomorrow’s digital businesses. Headquartered in Silicon Valley, GlobalLogic operates design studios and engineering centers around the world, extending our deep expertise to customers in the healthcare and life sciences, communications, financial services, automotive, technology, media and entertainment, manufacturing, and semiconductor industries. GlobalLogic is a Hitachi Group Company.
Inspira Technologies OXY B.H.N. Ltd.
Inspira Technologies is an innovative medical device company in the respiratory care industry. Inspira is developing the ART device, a cost effective early extracorporeal respiratory support system with an intent to function as an “Artificial Lung” for deteriorating respiratory patients. The ART device designed to utilize a hemo-protective flow approach aimed to rebalance saturation levels while patients are awake and breathing, potentially minimizing the patient’s need for mechanical ventilation. The Company’s product has not yet been tested or used in humans and has not been approved by the U.S. Food and Drug Administration (FDA). For more information, please visit our corporate website: https://inspira-technologies.com/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211013005237/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Riskified Named to the CNBC World's Top Fintech Companies 2026 List23.7.2026 14:00:00 CEST | Press release
Payment category recognition marks Riskified's continued presence among the world's leading fintech innovators Riskified (NYSE: RSKD), a global leader in ecommerce fraud detection and risk intelligence, has been named to CNBC's World's Top Fintech Companies 2026 list, in the Payments category. The list, now in its fourth edition, is produced by CNBC in partnership with Statista Inc., the global statistics and industry ranking firm. It was announced on July 22, 2026, and is available on CNBC's website. This is Riskified's second time making the list. The company previously earned this recognition in 2024, reinforcing its position in the ecommerce fraud and risk intelligence sector and underscoring its ongoing success in empowering businesses to grow revenue and profitability by mitigating risk through its AI-powered platform. CNBC and Statista's ranking covers the top 500 companies across eight fintech segments — Payments, Neobanking, Alternative Financing, Wealth Technology, Digital As
Azafaros Completes Enrollment of Phase 3 (NAVIGATE) Study Evaluating Nizubaglustat for the Treatment of Patients with GM1/GM2 Gangliosidoses23.7.2026 13:00:00 CEST | Press release
NAVIGATE comprises two pivotal Phase 3 studies investigating nizubaglustatRecruitment completed in Phase 3 registrational study in patients with late-infantile and juvenile GM1/GM2 gangliosidosesEnrollment in Niemann-Pick type C disease (NPC) Phase 3 study is ongoingTopline data from GM1/GM2 gangliosidoses Phase 3 study is anticipated in early 2028 Azafaros, a private company building a portfolio of disease-modifying therapeuticsto become a leader in lysosomal storage disorders (LSDs) focused on addressing neurological symptoms, today announced the completion of patient recruitment in its Phase 3 study evaluating nizubaglustat for the treatment of GM1/GM2 gangliosidoses. “Completing enrollment in our Phase 3 GM1/GM2 study is a significant step toward potentially bringing nizubaglustat to patients and families living with these devastating neurodegenerative diseases," said Stefano Portolano, Chief Executive Officer at Azafaros. "We are deeply grateful to the patients, caregivers, invest
Francisco Partners Closes $21 Billion Across Flagship and Agility Funds23.7.2026 13:00:00 CEST | Press release
Largest fundraise in the firm’s history brings total capital raised to more than $75 billion Francisco Partners (“FP”), a leading global investment firm that specializes in partnering with technology companies, today announced the closing of $21 billion in capital commitments across its Francisco Partners VIII, L.P. flagship fund and Francisco Partners Agility IV, L.P., its middle-market fund. FP exceeded its initial targets of $14.0 billion and $3.5 billion, respectively. This milestone builds on Francisco Partners' longstanding track record of performance, underscored by its distinction as the only firm to rank among the top three performers in each of the past six HEC-Dow Jones Large Buyout Performance Rankings.* “In our business, long-term success is created through a series of relationships built on years of trust and collaboration," said Dipanjan (“DJ”) Deb, Co-Founder and CEO of Francisco Partners. "We want to thank our investors for their support, our management teams for their
Taiwanese ensembles showcase erhu and ocarina at Prague Folklore Days23.7.2026 10:21:00 CEST | Press release
The Prague Folklore Days 2026 was held on July 17 and 18 in the heart of Prague, bringing together 56 international arts groups from Germany, Austria, Slovakia, Spain, the Netherlands, and Poland. Four Taiwanese groups took part: Hildebrand Yu’s ocarina band, the Shi-xian Huqin Orchestra, the Taipei Folk Orchestra, and the Four Strings Ensemble. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722841530/en/ Taiwanese ensembles showcase erhu and ocarina at Prague Folklore Days Led by Huang Chun-sin, the official Taiwan representative band featured a diverse lineup of ocarina, erhu, and dance performers. Their program stood out among the European groups with its distinctive character and vivid stage presence. Hildebrand Yu’s ocarina band captivated audiences with warm, uplifting melodies accompanied by the ocarina and ukulele. Yu also performed “Twilight Waltz,” delivering a heartfelt piece of poetic expression, like sunlight
Taiwan Children’s Choirs Garner Major Awards at Hungarian Choral Competition23.7.2026 09:33:00 CEST | Press release
Competing against 36 leading contenders from 20 countries, four Taiwanese children’s choirs have garnered several major awards and top honors at the 5th Budapest International Choral Celebration, showcasing Taiwan’s cultural diversity and music excellence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722613876/en/ Puzangalan Children’s Choir and Yo Wu Wei Children’s Chorus join forces with international choral ensembles and orchestras to perform Mozart’s Requiem Mass in D minor, K. 626 at the Béla Bartók National Concert Hall of Müpa Budapest. With its pure, angelic voices and exceptional vocal techniques, Puzangalan Children’s Choir from Pingtung County won the top prize, Laurea Summa Cum Laude, in the Grand Prix Competition’s Youth Choir of Equal Voices, Folklore, and Sacred Music categories. In the Open Competition, Yo Wu Wei Children’s Chorus claimed three gold prizes in the categories of Youth Choir of Equal Voices
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom